Kyle Doherty


New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Infigratinib Opens Up Options for Patients With FGFR2-Mutant Cholangiocarcinoma

July 29th 2021

Milind Javle, MD, discusses the potential impact of infigratinib on the treatment landscape of FGFR2 fusion–positive cholangiocarcinoma.

Investigators Explore the Role of VS-6766 and Defactinib in KRAS-Mutant NSCLC

July 21st 2021

Patients with non-small cell lung cancer harboring KRAS mutations have been an underserved population with few treatment options, specifically those with G12V mutations.

Dostarlimab Expands Options for dMMR Endometrial Cancer

July 14th 2021

Patients with mismatch repair–deficient recurrent or advanced endometrial cancer gained an efficacious and safe treatment option with the addition of dostarlimab-gxly.

Neoadjuvant Apalutamide Does Not Interfere With Robotic Prostatectomy

July 12th 2021

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Copanlisib/Rituximab Combination Demonstrates Superiority Across iNHL

July 9th 2021

Copanlisib plus rituximab exhibited a manageable safety profile and superior efficacy in patients with relapsed indolent non-Hodgkin lymphoma (iNHL) compared with rituximab plus placebo.

New Toolkit Aims to Help Employers Address Cancer Treatment

July 8th 2021

The National Comprehensive Cancer Network (NCCN) has launched a digital initiative to provide strategic approaches specifically geared toward employers who need to navigate a diagnosis of cancer among their staff.

The Understanding of Immunotherapy Biomarkers Is Rapidly Evolving in Oncology

June 29th 2021

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike.

Isatuximab Combination Looks to Improve Outcomes for Early Relapsed Multiple Myeloma

June 28th 2021

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

Axi-cel Elicits Durable Response in Relapsed/Refractory FL

June 16th 2021

Henry Chi Hang Fung, MD, discusses how the durable response of axi-cel fills an unmet need for this patient population and the potentially exciting future of the therapy.

Kaiku Health and Novartis Collaborate on Specialized Digital Patient Monitoring Technology

June 15th 2021

Kaiku Health has announced that they are partnering with the global healthcare company Novartis to develop a digital patient monitoring and management system specifically for patients with melanoma who are receiving BRAF/MEK combination therapies.

Front-MIND Aims to Examine Tafasitamab Triplet in DLBCL

June 14th 2021

Tafasitamab-cxix plus lenalidomide and R-CHOP may have synergistic potential and could represent a potential future treatment option for patients with newly diagnosed diffuse large B-cell lymphoma.

C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL

June 8th 2021

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

Nivolumab Plus Chemotherapy Outperforms Chemotherapy Alone in Resectable NSCLC

June 6th 2021

Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Zenocutuzumab Demonstrates Clinical Activity in a Variety of NRG1+ Cancers

June 5th 2021

Zenocutuzumab represents a promising novel targeted therapeutic option for patients with NRG1 fusion–positive cancers.

Catequentinib Shows Promise in Treatment of Advanced Synovial Sarcoma

June 4th 2021

Catequentinib improved disease control and progression-free survival in patients with advanced synovial sarcoma compared with dacarbazine.

TheraSphere Proves Highly Effective in HCC

June 3rd 2021

Siddharth Padia, MD, explaines TheraSphere’s unique mechanism of action and what its approval means in HCC and beyond.

Loncastuximab Tesirine Provides Alternative for Broad Range of Patients With DLBCL

June 1st 2021

Loncastuximab tesirine-lpyl (Zynlonta) exhibited significant clinical activity, including impressive response rates with tolerable safety, as a single agent in adult patients with relapsed/refractory large B-cell lymphoma that failed prior established therapies.

Larotrectinib Achieves High Marks in NTRK-Mutant Thyroid Cancer

May 24th 2021

Larotrectinib (Vitrakvi) has proved to be highly active in patients with thyroid cancer with NTRK gene fusions, exhibiting rapid and durable disease control.

COVID-19 Accommodations May Endure Long After the Pandemic

May 14th 2021

Opinion leaders provide a glimpse into the future of what approaches adopted during COVID-19 may persist in oncology after the pandemic ends.

Liso-cel Expands CAR T-Cell Options in Lymphoma

May 14th 2021

Amitkumar Mehta, MD, the safety profile of liso-cel and how it is advancing the relapsed/refractory large B-cell lymphoma treatment paradigm.

Ide-Cel Proves Highly Effective in Relapsed/Refractory Myeloma

May 13th 2021

Nikhil C. Munshi, MD, discusses how idecabtagene vicleucel has potentially marked the beginning of a new chapter for cellular therapy in multiple myeloma.

Tivozanib Boosts RCC Treatment Portfolio

May 10th 2021

Daniel J. George, MD, discussed how tivozanib differs from other TKIs and its potential to fill an unmet need in the treatment of patients with renal cell carcinoma.

COVID-19 Has Diverse Effects on Cancer Care

May 3rd 2021

OncologyLive® Advisory Board members speak about how COVID-19 has touched all aspects of oncology practice, research, and treatment.

Trilaciclib Tackles Myelosuppression in SCLC

May 1st 2021

Lowell L. Hart, MD, discusses trilaciclib’s unique role in patients with ES-SCLC who experience myelosuppression, as well as the future role of the agent.

TJ-CD4B Aims to Expand the Bispecific Antibody Portfolio as Phase 1 Trial Kicks Off

April 27th 2021

I-Mab Biopharma and ABL Bio, Inc set their sights on adding the bispecific antibody, TJ-CD4B, to the expanding armamentarium for patients with various types of advanced and metastatic solid cancers.

Melphalan Flufenamide Emerges as Option for Heavily Pretreated Myeloma

April 22nd 2021

Joseph Mikhael, MD, MEd, FRCPC, FACP, discussed how melphalan flufenamide could potentially shift the treatment paradigm for patients with multiple myeloma.

Umbralisib Expands the Treatment Landscape for Non-Hodgkin Lymphomas

April 21st 2021

A favorable risk profile and clinically meaningful response rates have made umbralisib a new therapeutic option for patients with heavily pretreated indolent non-Hodgkin lymphomas.

Neratinib Plus Fulvestrant Fails to Meet Efficacy Threshold in ER+ Metastatic Breast Cancer

April 12th 2021

Neratinib in combination with fulvestrant was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, although the clinical benefit rate did not meet the predefined efficacy criteria.

Selinexor, Bortezomib, and Dexamethasone Combination Proves Effective for Myeloma

April 7th 2021

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.